Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United Kingdom

Journal of Clinical Microbiology

Volumn 50, Issue 8, 2012, Pages 2639-2644

  Borman, Andrew M ^a   Szekely, Adrien ^a   Palmer, Michael D ^a   Johnson, Elizabeth M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGAR MEDIUM; ANALYTICAL ERROR; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CLINICAL LABORATORY; CRYPTOCOCCUS NEOFORMANS; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; PYROSEQUENCING; SACCHAROMYCES CEREVISIAE; SPECIES DIFFERENCE; UNITED KINGDOM; YEAST;

DIAGNOSTIC ERRORS; GREAT BRITAIN; HEALTH SERVICES RESEARCH; HUMANS; LABORATORY PROFICIENCY TESTING; MICROBIOLOGICAL TECHNIQUES; MYCOLOGY; MYCOSES; YEASTS;

EID: 84864414990     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00913-12     Document Type: Article

References (37)

1. Arendrup MC, Denning DW. 2007. Does one voriconazole breakpoint suit all Candida species? J. Clin. Microbiol. 45:2093-2094.
2. Arendrup MC, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. 2009. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob. Agents Chemother. 53:1628-1629.
3. Arendrup MC, et al. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion and agar diffusion methods with RPMI and IsoSensitest media. Antimicrob. Agents Chemother. 54:426-439.
4. Borman AM, et al. 2010. Rapid molecular identification of pathogenic yeast species by pyrosequencing analysis of 35 nucleotides of the internal transcribed spacer 2. J. Clin. Microbiol. 48:3648-3653.
5. Borman AM, et al. 2009. Pyrosequencing analysis of 20 nucleotides of internal transcribed spacer 2 discriminates Candida parapsilosis, Candida metapsilosis, and Candida orthopsilosis. J. Clin. Microbiol. 47:2307-2310.
6. Borman AM, et al. 2008. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J. Clin. Microbiol. 46:933-938. (Pubitemid 351379982)
7. Campbell CK, Davey KG, Holmes AD, Szekely AA, Warnock DW. 1999. Comparison of the API Candida system with the AUXACOLOR2 system for identification of common yeast pathogens. J. Clin. Microbiol. 37:821-823. (Pubitemid 29091317)
8. Campbell CK, Holmes AD, Davey KG, Szekely A, Warnock DW. 1998. Comparison of a new chromogenic agar with the germ tube method for presumptive identification of Candida albicans. Eur. J. Clin. Microbiol. Infect. Dis. 17:367-368. (Pubitemid 28379329)
9. Desnos-Ollivier M, et al. 2008. Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J. Clin. Microbiol. 46:3237-3242.
10. Freydiere AM, Guinet R, Boiron P. 2001. Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med. Mycol. 39:9-33. (Pubitemid 32192914)
11. Fromtling RA. 1995. Mycology, p 697-855. In Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (ed), Manual of clinical microbiology, 6th ed. ASM Press, Washington, DC.
12. Garey KW, et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31. (Pubitemid 43939072)
13. Gray LD, Roberts GD. 1988. Laboratory diagnosis of systemic fungal diseases. Infect. Dis. Clin. North Am. 2:779-803.
14. Jensen RH, Arendrup MC. 2011. Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J. Clin. Microbiol. 49:549-556.
15. Linton CJ, et al. 2007. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the UK Mycology Reference Laboratory. J. Clin. Microbiol. 45:1152-1158. (Pubitemid 46626478)
16. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. 2008. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J. Clin. Microbiol. 46:2659-2664.
17. Marr KA. 2004. Invasive Candida infections: the changing epidemiology. Oncology 14:9-14.
18. Morrell M, Fraser VJ, Kollef MH. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob. Agents Chemother. 49:3640-3645. (Pubitemid 41233011)
19. Nucci M, Marr KA. 2005. Emerging fungal diseases. Clin. Infect. Dis. 41:521-526. (Pubitemid 41099648)
20. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
21. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618. (Pubitemid 47299877)
22. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. 2011. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J. Clin. Microbiol. 49:3800-3804.
23. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. (Pubitemid 46167771)
24. Pfaller MA, Diekema DJ. 2010. Wild-type MIC distributions and epidemiological cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr. Fungal Infect. Rep. 4:168-174.
25. Pfaller MA, et al. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal of interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
26. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
27. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
28. Pfaller MA, et al. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol. Infect. Dis. 70:330-343.
29. Pfaller MA, et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J. Clin. Microbiol. 49:630-637.
30. Pfaller MA, et al. 1999. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participaant Group (Europe). Diagn. Microbiol. Infect. Dis. 35:19-25. (Pubitemid 29435937)
31. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. 1998. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 31:327-332. (Pubitemid 28212061)
32. Ruhnke M. 2006. Epidemiology of Candida albicans infections and role of non-Candida albicans yeasts. Curr. Drug Targets 7:495-504. (Pubitemid 43744840)
33. Snydman DR. 2003. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 123:500S-503S. (Pubitemid 36549820)
34. Valenza G, et al. 2008. Evaluation of new colorimetric Vitek 2 yeast identification card by use of different source media. J. Clin. Microbiol. 46:3784-3787.
35. Verweij PE, Breuker JM, Rijs AJMM, Meis JFGM. 1999. Comparative study of seven commercial yeast identification systems. J. Clin. Pathol. 52:271-273. (Pubitemid 29161489)
36. Wingard JR. 1994. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. 19(Suppl 1):49-53.
37. Wright WL, Wenzel RP. 1997. Nosocomial Candida. Epidemiology, transmission and prevention. Infect. Dis. Clin. North Am. 11:411-425. (Pubitemid 27285710)